Paytient
PrivateLast Round
Growth Equity
Jun 3, 2025
Total Funding Raised
$102.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Paytient operates in FinTech and is based in Columbia, Missouri. Its latest recorded funding round was a Growth Equity round in June 2025.
Paytient is a fintech company that provides employer- or health plan-embedded payment solutions that allow members to pay for out-of-pocket medical, dental, vision, pharmacy, and veterinary expenses over time without interest or fees.
Sector
FinTech
Verticals
Lending & Credit, Digital Payments, BNPL
Business Model
B2B2C
Customer Profile
Payment Processing Fee, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paytient Comparables
Compare Paytient with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| medZERO | 87% | |
| PayZen | 84% | |
| Nibble Health | 80% |
For institutional investors. Book with your work email.
Paytient Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Jun 3, 2025 | ||||
| Debt | Jul 13, 2023 | ||||
| Series B | Jan 10, 2023 | ||||
| Series A | Jul 1, 2021 | ||||
| Seed | Oct 1, 2020 | ||||
Pre Seed | Jun 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Paytient Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bertelsmann Investments | Series B |
| Mercato Partners | Series B |
| Lightbank | Series A, Seed, Series B, Pre Seed |
| Cultivation Capital | Series A, Seed, Series B, Pre Seed |
| Crossbeam Venture Partners | Series B |
| Initialized Capital Management | Series B |
| Trinity Capital | Growth Equity |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 22, 2026
Now part of nearly 6,000 employer health plans.
- Mar 8, 2026
Added Fifth Third Bank, a financial services firm, as a customer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 6, 2026
On Oct 6th '26 in Missouri, Fast Company names Paytient to its Next Big Things in Tech list in the Health and Medicine Category, recognizing breakthrough technologies with the potential to transform industries.
For institutional investors. Book with your work email.
Paytient Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Paytient's valuation, stock price, and market status.
Is Paytient a public or private company?
Paytient is a private company.
What is the current stock price of Paytient?
Paytient is a private company, so its shares have no public market price. Caplight tracks Paytient's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Paytient worth (valuation)?
Valuation information for Paytient is not publicly available.
Can I buy Paytient stock?
Paytient shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Paytient's last funding round?
Paytient's most recent funding round was Growth Equity on June 3, 2025.
Who are the main investors in Paytient?
Key investors in Paytient include Mercato Partners, Lightbank, Cultivation Capital, Inspired Capital, Silicon Valley Bank.
Will Paytient IPO soon?
No public IPO plans have been announced for Paytient.
How can I track Paytient secondary market activity?
Caplight tracks bids, offers, and trades in Paytient's shares on secondary markets.